US pharma major Eli Lilly (NYSE: LLY) today announced a definitive agreement to acquire Verve Therapeutics (Nasdaq: VERV), a Boston-based clinical-stage company developing genetic medicines for cardiovascular disease, sending Verve’s shares up 77.7% to $11.15 in premarket trading.
Verve is developing a pipeline of gene editing medicines designed to address the drivers of atherosclerotic cardiovascular disease (ASCVD) through treatments that may only need to be given once in a lifetime. Verve's lead program (VERVE-102) is a potential first-in-class in vivo gene editing medicine targeting PCSK9, a gene linked to cholesterol levels and cardiovascular health. VERVE-102 is being evaluated in a Phase Ib clinical trial study and has been granted Fast Track designation by the US Food and Drug Administration.
Lilly said it will commence a tender offer to acquire all of the outstanding shares of Verve for $10.50 per share in cash (an aggregate of around $1.0 billion) payable at closing, plus one non-tradeable contingent value right (CVR) per share that entitles the holder to receive up to an additional $3.00 per share.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze